Merck announced that the Phase III KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resected stage IIB and IIC melanoma met its key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis.
[Merck & Co., Inc.]